




## Stealth LNPs have long circulation times enabling a platform approach to target specific cell types




## Comparing multiple targeting ligand formats with varying affinities to ASGPR and off-target receptors




## The number of ligands per LNP can be titrated for optimal expression *in vitro*




## A modular bioconjugation platform transforms the stealth LNP into a ctLNP




## Linker chemistry 1 demonstrates higher activity across multiple stealth LNPs with both scFv-1 and VHH-1




## ASGPR targeting scFv and VHH show higher liver expression than GalNAc<sub>3</sub> in mice



## Uptake and expression of mRNA was monitored using DiD containing LNPs encapsulating mFLuc



## Longer ligand spacers facilitate higher uptake and expression into primary hepatocytes



## Next generation stealth formulations reduce background expression while enhancing on target potency

